Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 1,906 Shares

Key Points

• Natera CFO Michael Brophy sold 1,906 shares at an average price of $425.55, generating approximately $811,098. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, leaving him with 46,574 shares.
• Natera shares fell 5.0% to $414.30, despite trading near a 52-week high and remaining well above their 50-day and 200-day moving averages.
• The company reported quarterly revenue of $752.75 million, up 37.7% year over year, and narrowed its loss to $0.47 per share versus expectations of $0.49. Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $394.31.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Brophy sold 1,906 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $425.55, for a total value of $811,098.30. Following the completion of the sale, the chief financial officer directly owned 46,574 shares in the company, valued at $19,819,565.70. This represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The stock was sold at an average price of $426.34, for a total value of $510,755.32.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total value of $317,086.00.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The shares were sold at an average price of $274.22, for a total value of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The shares were sold at an average price of $267.99, for a total value of $84,952.83.

Natera Trading Down 5.0%

NTRA stock traded down $21.70 during trading on Friday, reaching $414.30. 2,431,930 shares of the company's stock were exchanged, compared to its average volume of 1,559,061. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The company's fifty day moving average price is $377.06 and its 200-day moving average price is $266.44.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company earned ($0.74) earnings per share. As a group, research analysts expect that Natera, Inc. will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Provenance Wealth Advisors LLC acquired a new stake in shares of Natera in the 3rd quarter valued at $89,000. Factory Mutual Insurance Co. acquired a new position in Natera during the third quarter worth $491,000. Aware Super Pty Ltd as trustee of Aware Super acquired a new position in Natera during the third quarter worth $6,620,000. Greenleaf Trust acquired a new position in Natera during the third quarter worth $240,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Natera during the third quarter valued at about $7,545,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. BTIG Research boosted their price objective on Natera from $320.00 to $430.00 and gave the stock a "buy" rating in a research note on Tuesday. Wells Fargo & Company raised their target price on Natera from $220.00 to $284.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. UBS Group lifted their target price on Natera from $290.00 to $435.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. Guggenheim boosted their price target on shares of Natera from $360.00 to $475.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. Finally, Barclays upped their price target on shares of Natera from $340.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $394.31.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.